Anecortave Acetate Update
There are many promising macular degeneration treatments that fall by the wayside during careful testing. That is why we at VisiVite.com base our vitamin supplements on successful published scientific research.
A case in point is for Anecortave Acetate, a steroid analog manfactured by Alcon.
After two studies showing no benefit to patients with macular degeneration, the FDA announced in July 2008 that Alcon has terminated development of anecortave acetate as a treatment to lower the risk of age-related macular degeneration.
The two studies performed with 2,546 patients over 24 months showed that anecortave acetate had no effect on the outcome of results of patients with macular degeneration.